Abstract
The use of helium in medicine was first described by Barach who treated obstructive lesions of the airways, in 1936. Since then, only scattered reports can be found in the medical literature until the 80s, when interest in helium resurged for the treatment of acute asthma, as deaths from this disease begun to rise. At least theoretically, because of its physical properties, helium should be useful in several obstructive conditions of the airways including upper airway obstruction, croup, post-extubation stridor, asthma attacks, exacerbations of chronic obstructive pulmonary disease (COPD), etc. However, there is not enough evidence to support the systematic use of heliox to treat severe stages or acute exacerbations of COPD in either ventilated or non ventilated patients because there is currently no convincing impact on patient outcome. Therefore, at present, widespread use of heliox cannot be recommended in clinical practice.
Keywords: COPD, expiratory flow limitation, exercise, mechanical ventilation, non-invasive ventilation, helium-oxygen gas mixtures
Current Respiratory Medicine Reviews
Title: Clinical Uses of Heliox Mixtures in Chronic Obstructive Pulmonary Disease
Volume: 5 Issue: 3
Author(s): Nickolaos G. Koulouris, Antonia Koutsoukou and Edgardo D'Angelo
Affiliation:
Keywords: COPD, expiratory flow limitation, exercise, mechanical ventilation, non-invasive ventilation, helium-oxygen gas mixtures
Abstract: The use of helium in medicine was first described by Barach who treated obstructive lesions of the airways, in 1936. Since then, only scattered reports can be found in the medical literature until the 80s, when interest in helium resurged for the treatment of acute asthma, as deaths from this disease begun to rise. At least theoretically, because of its physical properties, helium should be useful in several obstructive conditions of the airways including upper airway obstruction, croup, post-extubation stridor, asthma attacks, exacerbations of chronic obstructive pulmonary disease (COPD), etc. However, there is not enough evidence to support the systematic use of heliox to treat severe stages or acute exacerbations of COPD in either ventilated or non ventilated patients because there is currently no convincing impact on patient outcome. Therefore, at present, widespread use of heliox cannot be recommended in clinical practice.
Export Options
About this article
Cite this article as:
Koulouris G. Nickolaos, Koutsoukou Antonia and D'Angelo Edgardo, Clinical Uses of Heliox Mixtures in Chronic Obstructive Pulmonary Disease, Current Respiratory Medicine Reviews 2009; 5 (3) . https://dx.doi.org/10.2174/157339809788922379
DOI https://dx.doi.org/10.2174/157339809788922379 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cytokine Profile in Patients Infected with Anisakis simplex in Endemic Areas: Dietary Intervention with Polyphenols: A Working Hypothesis
Endocrine, Metabolic & Immune Disorders - Drug Targets Systems Biology Approaches and Metabolomics for Understanding Japanese Traditional Kampo Medicine
Current Pharmacogenomics and Personalized Medicine STAT3 as a Therapeutic Target for Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry The Preclinical Testing Strategy for the Development of Novel Chemical Entities for the Treatment of Asthma
Current Drug Targets Challenges and Successes Using Nanomedicines for Aerosol Delivery to the Airways
Current Gene Therapy Generation and Characterization of Monoclonal Antibodies Against Tth DNA Polymerase and its Application to Hot-Start PCR
Protein & Peptide Letters Rapid Desensitization of Hypersensitivity Reactions to Chemotherapy Agents.
Current Drug Safety Green Tea Polyphenols as an Anti-Oxidant and Anti-Inflammatory Agent for Cardiovascular Protection
Cardiovascular & Hematological Disorders-Drug Targets Contrasting Roles of the Galectin-3 in the Schizophrenia Onset, Clinical Presentation, and Somatic Comorbidity
Current Topics in Medicinal Chemistry Molecular and Biotechnological Advances in Milk Proteins in Relation to Human Health
Current Protein & Peptide Science Hypersensitivity to Antineoplastic Agents
Current Pharmaceutical Design The Anti-Inflammatory Potential of ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Evidence from Basic and Clinical Research
Current Drug Targets Evaluating Safety of Long-Acting Beta Agonists (LABAs) in Patients with Asthma
Current Drug Safety Use of Phase III Slope of Volumetric Capnography in Outpatient Clinical Practice: A Descriptive Analysis
Current Respiratory Medicine Reviews Treatment for Radiation-Induced Pulmonary Late Effects: Spoiled for Choice or Looking in the Wrong Direction?
Current Drug Targets Understanding Membrane Protein Drug Targets in Computational Perspective
Current Drug Targets Blocking Leukocyte Rolling: Does it have a Role in Disease Prevention?
Vascular Disease Prevention (Discontinued) Medicinal Plants against Ischemic Stroke
Current Pharmaceutical Biotechnology Nanocarriers for Respiratory Diseases Treatment: Recent Advances and Current Challenges
Current Topics in Medicinal Chemistry SiRNA Mediated Gene Silencing: Hurdles, Strategies and Applications
Pharmaceutical Nanotechnology